0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover245.65%IV-142.72%PremiumDec 20, 2024Expiry Date5.88Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9047Delta0.0770Gamma0.69Leverage Ratio-0.0093Theta-0.0033Rho-0.63Eff Leverage0.0016Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet